The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION. The new alert aims to warn patients and doctors about a rare eye condition that can lead to sudden, permanent vision. The FDA has mandated GLP-1 drugmakers to warn about NAION, a rare optic nerve condition causing sudden vision loss, now associated with drugs like Ozempic and Wegovy.